Patents by Inventor Charles David Hartley

Charles David Hartley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180289718
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Patent number: 10016439
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 10, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji Saito, Masato Higashino, Soichi Kawaharada, Arwel Lewis, Mark Stuart Chambers, Alastair Rae, Kim Louise Hirst, Charles David Hartley
  • Publication number: 20160331757
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: January 30, 2015
    Publication date: November 17, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Publication number: 20100267755
    Abstract: The invention provides the compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R1 and R2 are independently selected from the group consisting of H, C1-6alkyl, C1-2alkyl substituted by one to five fluorine atoms, C3-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl, C4-12bridged cycloalkyl, A(CR7R8)n and B(CR7R8)n; R3 is selected from the group consisting of C1-6alkyl, NH2 and R10CONH; R4 is C1-2alkyl substituted by one to five fluorine atoms; R5 is selected from the group consisting of H, C1-4alkyl, C1-2alkyl substituted with one to five fluorine atoms, halogen and C3-10cycloalkylC0-6alkyl, with the proviso that when R6 is H R5 is not H.
    Type: Application
    Filed: May 23, 2002
    Publication date: October 21, 2010
    Applicants: GLAXO GROUP LIMITED, Jennifer Margaret GREEN
    Inventors: Gianpaolo Bravi, Malcolm Clive Carter, Richard Howard Green, Jennifer Margaret Doughty, Charles David Hartley, Alan Naylor, Martin Pass, Jeremy John Payne, Neil Anthony Pegg
  • Publication number: 20090274655
    Abstract: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.
    Type: Application
    Filed: November 15, 2007
    Publication date: November 5, 2009
    Inventors: Richard Martin Grimes, Charles David Hartley, Jacqueline Elizabeth Mordaunt, Pritom Shah, Martin John Slater, Gemma Victoria White
  • Publication number: 20090227600
    Abstract: Anti-viral agents of Formula (Ia) wherein: A represents hydroxy; B represents C(O)R3 wherein R3 is 4-tert-butyl-3-methoxyphenyl; D represents 1,3-thiazol-2-yl or 5-methyl-1,3-thiazol-2-yl; E represents pyrazin-2-yl; G represents 1,3-thiazol-2-ylmethyl, 1,3-thiazol-4-ylmethyl, 1,2-thiazol-3-ylmethyl, or 1H-pyrazol-1-ylmethyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl, processes for their preparation and their use in HCV treatment are provided.
    Type: Application
    Filed: October 24, 2005
    Publication date: September 10, 2009
    Inventors: Rossella Guidetti, David Haigh, Charles David Hartley, Peter David Howes, Fabrizio Nerozzi, Stephen Allan Smith
  • Publication number: 20090136448
    Abstract: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.
    Type: Application
    Filed: December 20, 2006
    Publication date: May 28, 2009
    Inventors: John Andrew Corfield, Richard Martin Grimes, David Harrison, Charles David Hartley, Peter David Howes, Joelle Le, Malcolm Lees Meeson, Jacqueline Elizabeth Mordaunt, Pritom Shah, Martin John Slater, Gemma Victoria White
  • Patent number: 7304087
    Abstract: Anti-viral agents of Formula (I) wherein: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C1-6alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or optionally substituted C1-6alkyl; J represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl; processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: December 4, 2007
    Assignee: Glaxo Group Limited
    Inventors: David Haigh, Charles David Hartley, Peter David Howes, Deborah Lynette Jackson, Pritom Shah, Martin John Slater
  • Patent number: 7259163
    Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 21, 2007
    Assignee: Glaxo Group Limited
    Inventors: Gianpaolo Bravi, Rossella Guidetti, David Haigh, Charles David Hartley, Peter David Howes, Deborah Lynette Jackson, Victoria Lucy Helen Lovegrove, Pritom Shah, Martin John Slater, Katrina Jane Wareing
  • Patent number: 7074802
    Abstract: The invention thus provides the compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R1 and R2 are independently selected from the group consisting of H, C1-6alkyl, C2-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl and C4-12bridged cycloalkyl; R3 is selected from the group consisting of C1-6alkyl, NH2 and R5CONH; R4 is selected from the group consisting of CH2F, CHF2, CF3CH2, CF3CHF and CF3CF2; and R5 is selected from the group consisting of H, C1-6alkyl, C1-6alkoxy, C1-6alkylOC1-6alkyl, phenyl, HO2CC1-6alkyl, C1-6alkylOCOC1-6alkyl, C1-6alkylOCO, H2NC1-6alkyl, C1-6alkylOCONHC1-6alkyl and C1-6alkylCONHC1-6alkyl. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: July 11, 2006
    Assignee: Glaxo Group Limited
    Inventors: Jennifer Doughty, legal representative, Charles David Hartley, Alan Naylor, Jeremy John Payne, Neil Anthony Pegg, Richard Howard Doughty, deceased
  • Patent number: 6780869
    Abstract: The invention provides the compounds of formula (I) and pharmaceutically acceptable derivatives thereof, in which: R1 and R2 are independently selected from H, C1-6 alkyl, C2-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl or C4-12bridged cycloalkane; and R3 is C1-6alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of pain, fever, inflammation and a variety of conditions and diseases.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 24, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Richard Howard Green, Charles David Hartley, Alan Naylor, Jeremy John Payne, Neil Anthony Pegg
  • Publication number: 20040063745
    Abstract: Therapeutically active thiazole derivatives of formula (I) wherein R1, R2, X and X′ are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterized by overexpression of transforming growth factor &bgr;(TAG-&bgr;), and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventors: Francoise Jeanne Gellibert, Charles David Hartley, Neil Mathews, James Michael Woolven
  • Publication number: 20040063949
    Abstract: Therapeutically active pyrazole derivatives of formula (I) wherein R1-R3 are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor (TGF-), and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventors: Francoise Jeanne Gellibert, Charles David Hartley, Neil Mathews, James Michael Woolven